First-line treatment selection with organoids of an EGFR m + TP53 m stage IA1 patient with early metastatic recurrence after radical surgery and follow-up

Affiliations

• ¹ Department of Thoracic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.
• ² Eight-Year MD Program, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.
• ³ Medical Research Center, Central Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.
• ⁴ Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.
• ⁵ Accurate International Biotechnology Co. Ltd., Guangzhou, China.
• ⁶ Burning Rock Biotechnology Co. Ltd., Guangzhou, China.
• ⁷ Department of Medical Oncology/Haematology, Evang. Kliniken Essen-Mitte, Essen, Germany.
• ⁸ Division of Thoracic Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy.
• ⁹ Division of Medical Oncology, "S.G. Moscati" Hospital, Contrada Amoretta, 83100, Avellino, Italy.
• ¹⁰ Division of Thoracic Surgery, Department of Surgery, Keio University School of Medicine, Tokyo, Japan.